HPV Infection Prevention

Translate to Spanish or other 102 languages!

Most HPV infections (9 out of 10) go away by themselves within 2 years. But sometimes, HPV infections will last longer and can cause some cancers.  Image for illustration purposes
Most HPV infections (9 out of 10) go away by themselves within 2 years. But sometimes, HPV infections will last longer and can cause some cancers. Image for illustration purposes
- Advertisement -

HPV, or human papillomavirus, is a common virus that can cause cancers later in life. You can protect your child from these cancers with HPV vaccine at age 11–12 years.

HPV infections are common

HPV infections are very common. Nearly everyone will get HPV at some point in their lives.

  • More than 42 million Americans are infected with types of HPV that are known to cause disease.
  • About 13 million Americans, including teens, become infected each year.

HPV is spread through intimate skin-to-skin contact. You can get HPV by having vaginal, anal, or oral sex with someone who has the virus, even if they don’t have signs or symptoms.

- Advertisement -

Some HPV infections can lead to cancer

Most HPV infections (9 out of 10) go away by themselves within 2 years. But sometimes, HPV infections will last longer and can cause some cancers. HPV infections can cause cancers of the:

  • Cervix, vagina, and vulva
  • Penis
  • Anus
  • Back of the throat (called oropharyngeal cancer), including the base of the tongue and tonsils

Every year in the United States, HPV causes about 36,000 cases of cancer in both men and women.

Prevent cancer with HPV vaccine

CDC recommends two doses of HPV vaccine at ages 11–12 years. HPV vaccination can be started at age 9 years.

Children who get the first dose before their 15th birthday only need two doses. Teens who get the first dose on or after their 15th birthday need three doses.

- Advertisement -

The HPV vaccine series is most effective when given before a person is exposed to the virus.

Information Source: CDC

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

New Therapy for Head and Neck Squamous Cell Carcinoma Receives Accelerated FDA Approval

The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.

DHR Health to Host 13th Annual Circle of Care Caregivers Conference

DHR Health Rehabilitation Hospital will host its 13th Annual Circle of Care Caregivers Conference on Saturday, November 7, 2026, at the Edinburg Conference Center at Renaissance, offering educational presentations and resources for individuals caring for family members and loved ones.

HHS Opens $1 Million Funding Opportunity to Strengthen Women’s Preventive Care

The U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), announced a Notice of Funding Opportunity (NOFO) for the Women’s Initiative for Screening and Health (WISH) program.

Coordinated Care Supports Mother through Cancer and Pregnancy

Mega Doctor News By Kristen Zapata | UT Health San Antonio Two pink...
- Advertisement -